Advertisement

Diarrhea and Constipation: Supportive Oncology Management

  • Al B. BensonIII
  • Regina Stein
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Gastrointestinal toxicity is often a complication of cancer and its treatment. It is a common complaint of patients being treated with tumor-directed therapy and requires appropriate supportive care. Approximately 148,600 cases of colorectal cancer are diagnosed annually. The sequelae of disease progression and the toxicity of treatment can result in significant gastrointestinal complications. Inadequate assessment and treatment can lead to debilitating symptoms and significantly impact quality of life. This chapter will review two common complaints encountered in patients with gastrointestinal malignancies: diarrhea and constipation. Strategies will be discussed for effective palliation and treatment of these common conditions.

Keywords

Chemotherapy-related toxicity Diarrhea Constipation Treatment of gastrointestinal side effects Supportive oncology 

References

  1. 1.
    Guerrant RL, Gilder TV . et al. 2001; Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331PubMedCrossRefGoogle Scholar
  2. 2.
    Hogan CM. 1998; The nurse’s role in diarrhea management. Oncol Nurs Forum 25:879–886PubMedGoogle Scholar
  3. 3.
    DuPont HL. 1997; Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 92:1962–75PubMedGoogle Scholar
  4. 4.
    Benson AB, 3rd, Ajani JA, Catalano RB,. et al. 2004; Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918PubMedCrossRefGoogle Scholar
  5. 5.
    Arbuckle RB, Huber SL, Zacker C. 2000; The consequences of diarrhea occurring during chemotherapy for colorectal cancer: A retrospective study. Oncologist 5:250–259PubMedCrossRefGoogle Scholar
  6. 6.
    Milles SS, Muggia AL, Spiro HM. 1962; Colonic histological changes induced by 5-fluorouracil. Gastroenterology 43:391Google Scholar
  7. 7.
    Rothenberg ML, Meropol NJ, Poplin EA,. et al. 2001; Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMedGoogle Scholar
  8. 8.
    Common Toxicity Criteria, version 2.0. Http://ctep.cancer.gov/forms/CTCv20_4–30–992.pdfGoogle Scholar
  9. 9.
    Kulke MH, Mayer RJ. 1999; Carcinoid tumors. N Engl J Med 340:858PubMedCrossRefGoogle Scholar
  10. 10.
    Akerstrom G, Hellman P. et al. 2005; Management of midgut carcinoids. J Surg Oncol 89:161–169PubMedCrossRefGoogle Scholar
  11. 11.
    Janson ET. 2006; Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 9:249–256PubMedCrossRefGoogle Scholar
  12. 12.
    Bartlett JG. 2002; Antibiotic-associated diarrhea. N Engl J Med 346:334PubMedCrossRefGoogle Scholar
  13. 13.
    Kelly CP, Pothoulakis CN,. et al. 1994; Clostridium difficile colitis. N Engl J Med 330:(4)257–262PubMedCrossRefGoogle Scholar
  14. 14.
    Rao SS. 2003; Constipation: Evaluation and treatment. Gastroenterol Clin North Am 32:(2)659–683PubMedCrossRefGoogle Scholar
  15. 15.
    Hsieh C. 2005; Treatment of constipation in older adults. Am Fam Physician 72:(11)2277–2284PubMedGoogle Scholar
  16. 16.
    Hull C, Greco RS, Brooks DL. 1980; Alleviation of constipation in the elderly by dietary fiber supplementation. J Am Geriatr Soc 28:(9)410–414PubMedGoogle Scholar
  17. 17.
    Barnes PM, Powell-Griner E, McFann K, Nahin RL. 2004Complementary and alternative medicine use among adults. Advance Data from Vital and Health Statistics, US Dept of Health and Human Services, Rockville, MD,Google Scholar

Copyright information

© Humana Press, a part of Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Al B. BensonIII
    • 1
  • Regina Stein
    • 1
  1. 1.Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer CenterNorthwestern UniversitySuite 850USA

Personalised recommendations